Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy
It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with placebo (very low certainty).
1 finding from 1 review
RR 10.33 [2.15, 49.77]
21 participants
Very low
Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks · people with asthma
Anti‐IL13 or anti‐IL4 agents probably leads to lower exacerbation requiring hospitalisation or ED visit compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Change from baseline in blood eosinophils (cells x 10*9/L) · children and adults with asthma
1 finding from 1 review
Intervention not reported
Change from baseline in Periostin (ng/mL) · children and adults with asthma
1 finding from 1 review
Intervention not reported
Percentage reduction from baseline in maintenance OCS dose · children and adults with asthma
1 finding from 1 review
Intervention not reported
Post hoc exploratory endpoint: Exacerbation requiring hospitalisation/ED/OCS (rate ratio) · children and adults with asthma
The intervention may leads to lower post hoc exploratory endpoint: Exacerbation requiring… (low certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
Serious adverse events · people with asthma
Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · people with asthma
Anti‐IL13 or anti‐IL4 agents showed no clear difference in exacerbation requiring OCS (rate ratio) compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in ACQ score Scale: 0 to 6 (higher is worse) · people with asthma
1 finding from 1 review
Adverse events (any) · people with asthma
Anti‐IL13 or anti‐IL4 agents leads to higher adverse events (any) compared with placebo (high certainty).
1 finding from 1 review
Time off work or study · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Change from baseline in pre‐bronchodilator FEV1 · children and adults with asthma
1 finding from 1 review
Intervention not reported
Change from baseline in FENO (ppb) · children and adults with asthma
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
1 study · 5 participants
Very low
Death · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death compared with placebo (very low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death or disability after 12 months compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review